Hansteen V
Circulation. 1983 Jun;67(6 Pt 2):I57-60.
A randomized, double-blind, placebo-controlled trial of propranolol was carried out in 560 high-risk survivors of myocardial infarction enrolled at 12 Norwegian hospitals. The main purpose of the study was to determine the effect of propranolol, 160 mg/day, on the incidence of sudden cardiac death over 12 months. The patients were randomized 4-6 days after the acute event. A statistically significant reduction in sudden cardiac deaths of 52% was noted (11 deaths in the propranolol group and 23 in the placebo group). Four placebo patients and one propranolol patient were successfully resuscitated from ventricular fibrillation. In addition, less severe ventricular arrhythmias were significantly more common among the placebo-treated patients. Twenty-five patients in the treatment group and 37 in the control group died (p = 0.11). Severe adverse effects of the drug were uncommon in this high-risk population. The findings support the results of the Beta-Blocker Heart Attack Trial and other long-term beta-blocker trials in survivors of myocardial infarction.
在挪威12家医院招募的560名心肌梗死高危幸存者中进行了一项普萘洛尔的随机、双盲、安慰剂对照试验。该研究的主要目的是确定每天160毫克普萘洛尔对12个月内心脏性猝死发生率的影响。患者在急性事件发生后4 - 6天被随机分组。结果显示心脏性猝死发生率有统计学意义的显著降低，降低了52%（普萘洛尔组11例死亡，安慰剂组23例死亡）。4名安慰剂组患者和1名普萘洛尔组患者从心室颤动中成功复苏。此外，在接受安慰剂治疗的患者中，不太严重的室性心律失常明显更为常见。治疗组25例患者和对照组37例患者死亡（p = 0.11）。在这个高危人群中，该药物的严重不良反应并不常见。这些发现支持了β受体阻滞剂心肌梗死试验以及其他针对心肌梗死幸存者的长期β受体阻滞剂试验的结果。
